IMWG consensus on risk stratification in multiple myeloma

Research output: Contribution to journalArticlepeer-review

Standard

IMWG consensus on risk stratification in multiple myeloma. / Chng, W J; Dispenzieri, A; Chim, C-S; Fonseca, R; Goldschmidt, H; Lentzsch, S; Munshi, N; Palumbo, A; Miguel, J S; Sonneveld, P; Cavo, M; Usmani, S; Durie, B G M; Avet-Loiseau, H; IMWG ; Wheatley, Keith.

In: Leukemia, Vol. 28, No. 2, 02.2014, p. 269-77.

Research output: Contribution to journalArticlepeer-review

Harvard

Chng, WJ, Dispenzieri, A, Chim, C-S, Fonseca, R, Goldschmidt, H, Lentzsch, S, Munshi, N, Palumbo, A, Miguel, JS, Sonneveld, P, Cavo, M, Usmani, S, Durie, BGM, Avet-Loiseau, H, IMWG & Wheatley, K 2014, 'IMWG consensus on risk stratification in multiple myeloma', Leukemia, vol. 28, no. 2, pp. 269-77. https://doi.org/10.1038/leu.2013.247

APA

Chng, W. J., Dispenzieri, A., Chim, C-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., Cavo, M., Usmani, S., Durie, B. G. M., Avet-Loiseau, H., IMWG, & Wheatley, K. (2014). IMWG consensus on risk stratification in multiple myeloma. Leukemia, 28(2), 269-77. https://doi.org/10.1038/leu.2013.247

Vancouver

Chng WJ, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. https://doi.org/10.1038/leu.2013.247

Author

Chng, W J ; Dispenzieri, A ; Chim, C-S ; Fonseca, R ; Goldschmidt, H ; Lentzsch, S ; Munshi, N ; Palumbo, A ; Miguel, J S ; Sonneveld, P ; Cavo, M ; Usmani, S ; Durie, B G M ; Avet-Loiseau, H ; IMWG ; Wheatley, Keith. / IMWG consensus on risk stratification in multiple myeloma. In: Leukemia. 2014 ; Vol. 28, No. 2. pp. 269-77.

Bibtex

@article{032bb9c2f8044b6c8a7ce139e81ac482,
title = "IMWG consensus on risk stratification in multiple myeloma",
abstract = "Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.",
keywords = "Consensus Development Conferences as Topic, Humans, Multiple Myeloma, Prognosis",
author = "Chng, {W J} and A Dispenzieri and C-S Chim and R Fonseca and H Goldschmidt and S Lentzsch and N Munshi and A Palumbo and Miguel, {J S} and P Sonneveld and M Cavo and S Usmani and Durie, {B G M} and H Avet-Loiseau and IMWG and Keith Wheatley",
year = "2014",
month = feb,
doi = "10.1038/leu.2013.247",
language = "English",
volume = "28",
pages = "269--77",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - IMWG consensus on risk stratification in multiple myeloma

AU - Chng, W J

AU - Dispenzieri, A

AU - Chim, C-S

AU - Fonseca, R

AU - Goldschmidt, H

AU - Lentzsch, S

AU - Munshi, N

AU - Palumbo, A

AU - Miguel, J S

AU - Sonneveld, P

AU - Cavo, M

AU - Usmani, S

AU - Durie, B G M

AU - Avet-Loiseau, H

AU - IMWG

AU - Wheatley, Keith

PY - 2014/2

Y1 - 2014/2

N2 - Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

AB - Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.

KW - Consensus Development Conferences as Topic

KW - Humans

KW - Multiple Myeloma

KW - Prognosis

U2 - 10.1038/leu.2013.247

DO - 10.1038/leu.2013.247

M3 - Article

C2 - 23974982

VL - 28

SP - 269

EP - 277

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -